相似文献
1
Strep A: challenges, opportunities, vaccine-based solutions, and economics.
NPJ Vaccines. 2024 Apr 19;9(1):80. doi: 10.1038/s41541-024-00863-7.
2
The full health, economic, and social benefits of prospective Strep A vaccination.
NPJ Vaccines. 2023 Oct 30;8(1):166. doi: 10.1038/s41541-023-00758-z.
3
Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.
Vaccine. 2020 Feb 5;38(6):1384-1392. doi: 10.1016/j.vaccine.2019.12.005. Epub 2019 Dec 13.
4
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.
Drugs R D. 2024 Mar;24(1):1-12. doi: 10.1007/s40268-024-00452-y. Epub 2024 Mar 18.
5
A flow cytometry-based assay to determine the ability of anti-Streptococcus pyogenes antibodies to mediate monocytic phagocytosis in human sera.
J Immunol Methods. 2024 May;528:113652. doi: 10.1016/j.jim.2024.113652. Epub 2024 Mar 6.
6
Progress towards a glycoconjugate vaccine against Group A Streptococcus.
NPJ Vaccines. 2023 Mar 28;8(1):48. doi: 10.1038/s41541-023-00639-5.
7
[Evaluation of rapid diagnostic kits for the detection of group A streptococcus to Streptococcus pyogenes and Streptococcus spp. with Lancefield's group A antigen].
Kansenshogaku Zasshi. 2006 Nov;80(6):665-73. doi: 10.11150/kansenshogakuzasshi1970.80.665.
8
Antibiotic consumption for sore throat and the potential effect of a vaccine against group A Streptococcus: a systematic review and modelling study.
EBioMedicine. 2023 Dec;98:104864. doi: 10.1016/j.ebiom.2023.104864. Epub 2023 Nov 9.
9
Strep A: challenges, opportunities, vaccine-based solutions and economics.
NPJ Vaccines. 2024 Apr 19;9(1):81. doi: 10.1038/s41541-024-00864-6.
10
Streptolysin O Deficiency in Streptococcus pyogenes M1T1 Mutant Strain Attenuates Virulence in and Infection Models.
mBio. 2023 Feb 28;14(1):e0348822. doi: 10.1128/mbio.03488-22. Epub 2023 Feb 6.
引用本文的文献
1
Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain.
Rev Esp Quimioter. 2024 Dec;37(6):454-471. doi: 10.37201/req/067.2024. Epub 2024 Jul 30.
本文引用的文献
1
Antibiotic consumption for sore throat and the potential effect of a vaccine against group A Streptococcus: a systematic review and modelling study.
EBioMedicine. 2023 Dec;98:104864. doi: 10.1016/j.ebiom.2023.104864. Epub 2023 Nov 9.
2
The full health, economic, and social benefits of prospective Strep A vaccination.
NPJ Vaccines. 2023 Oct 30;8(1):166. doi: 10.1038/s41541-023-00758-z.
3
Update on the development of Group A Streptococcus vaccines.
NPJ Vaccines. 2023 Sep 14;8(1):135. doi: 10.1038/s41541-023-00730-x.
4
The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation efforts.
NPJ Vaccines. 2023 Aug 25;8(1):128. doi: 10.1038/s41541-023-00718-7.
5
A Strep A vaccine global demand and return on investment forecast to inform industry research and development prioritization.
NPJ Vaccines. 2023 Aug 9;8(1):113. doi: 10.1038/s41541-023-00690-2.
6
Modeling the potential health impact of prospective Strep A vaccines.
NPJ Vaccines. 2023 Jun 10;8(1):90. doi: 10.1038/s41541-023-00668-0.
7
Global economic burden per episode for multiple diseases caused by group A Streptococcus.
NPJ Vaccines. 2023 May 15;8(1):69. doi: 10.1038/s41541-023-00659-1.
8
Optimal global spending for group A Streptococcus vaccine research and development.
NPJ Vaccines. 2023 Apr 25;8(1):62. doi: 10.1038/s41541-023-00646-6.
9
Modalities of group A streptococcal prevention and treatment and their economic justification.
NPJ Vaccines. 2023 Apr 22;8(1):59. doi: 10.1038/s41541-023-00649-3.
10
Progress towards a glycoconjugate vaccine against Group A Streptococcus.
NPJ Vaccines. 2023 Mar 28;8(1):48. doi: 10.1038/s41541-023-00639-5.
Zotero 插件